Increasing Prevalence of Infectious Diseases and Emergence of Covid-19 to Augment Growth of Vaccine Adjuvant Market

 

Vaccine Adjuvant Market

In immunology, an adjuvant is any material that enhances and/or decreases the immune response to a vaccine or other agent. The word "adjuvant" derives from the Latin phrase adiuvare, which means to assist or help. The usual definition of an adjuvant in this context is a substance added to enhance the effectiveness of a biological agent or product in the process of eliciting an immune response.

Market Dynamics

Increasing prevalence of infectious diseases is expected to propel growth of the global vaccine adjuvant market. For instance, in May 2019, according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda’, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population.

Moreover, increasing adoption of adjuvant technologies is also expected to aid in growth of the market. For instance, in January 2021, Oragenics, a developer of antibiotics against infectious diseases and treatments for oral mucositis, entered into a material transfer agreement with Adjuvance Technologies for use of the adjuvant TQL1055 in Oragenics’ Terra CoV-2 vaccine against COVID-19. Similarly, in October 2020, Medigen Vaccine Biologics Corporation, a biopharmaceutical company, and Dynavax Technologies Corporation, a biopharmaceutical company focused on R&D in novel vaccines, announced that Medigen Vaccine Biologics Corporation has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan for its COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant.

Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global vaccine adjuvant market. For instance, globally, as of 9:55am CET, 4 March 2021, there have been 114,653,749 confirmed cases of COVID-19, including 2,550,500 deaths, reported to the World Health Organization. Moreover, R&D in novel vaccine dose sparing adjuvant is also expected to aid in growth of the market. For instance, in January 2021, Mountain Valley MD Holdings Inc., a biotech and life sciences company, filed a POROUS ALUMINUM NANO-STRUCTURED ADJUVANT patent to protect the company's work on vaccine dose sparing.

 Competitive Analysis

Major players operating in the global vaccine adjuvant market include, SEPPIC Inc., Novavax, Inc., Hayashibara Co., Ltd., SPI Pharma Inc., Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, OZ Biosciences, GlaxoSmithKline, Agenus, Inc., Brenntag Biosector, Spectrum Pharmaceuticals. Inc., Sigma Aldrich, Adjuatis, Vaxliant, Adjuvance Technologies, Inc., GlaxoSmithKline plc., Puma Biotechnology, Tj Kaiwei, Zhouyue, Aphios, and CSL Limited.

Major players operating in the global vaccine adjuvant market are focused on adopting various strategies to enhance their market share. For instance, in May 2020, GlaxoSmithKline announced plans to produce one billion doses in 2021 of its vaccine adjuvant system to support numerous COVID-19 vaccine candidates.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

Pressure Bandages Market : Global Industry Analysis and Opportunity Assessment

Botanical and Plant Derived Drugs Market by Source,Dosage - Global Industry Analysis,Size,Share